FO-004 / 3B Pharma - LARVOL DELTA

A study to investigate safety and anti-tumour activity of a Fibroblast Activation Protein (FAP)-targeting radiotracer (177Lu-FO-004) & Safety and Tolerability of a FAP imaging agent (68Ga-3BP-3940) in patients with advanced cancer. (ANZCTR) - P1 | N=56 | Recruiting | Sponsor: 3B Pharmaceuticals GmbH | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2026

Enrollment open • Trial initiation date • Oncology • Solid Tumor

A study to investigate safety and anti-tumour activity of a Fibroblast Activation Protein (FAP)-targeting radiotracer (177Lu-FO-004) in patients with advanced cancer. (ANZCTR) - P1 | N=56 | Not yet recruiting | Sponsor: 3B Pharmaceuticals GmbH

New P1 trial • Oncology • Solid Tumor